CA3248093A1 - ANTI-ALPHA-SYNUCLEIN THERAPEUTIC VACCINES - Google Patents

ANTI-ALPHA-SYNUCLEIN THERAPEUTIC VACCINES

Info

Publication number
CA3248093A1
CA3248093A1 CA3248093A CA3248093A CA3248093A1 CA 3248093 A1 CA3248093 A1 CA 3248093A1 CA 3248093 A CA3248093 A CA 3248093A CA 3248093 A CA3248093 A CA 3248093A CA 3248093 A1 CA3248093 A1 CA 3248093A1
Authority
CA
Canada
Prior art keywords
seq
peptide
vaccine composition
amino acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3248093A
Other languages
English (en)
French (fr)
Inventor
Andrea Pfeifer
Maxime Ayer
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of CA3248093A1 publication Critical patent/CA3248093A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3248093A 2022-02-09 2023-02-09 ANTI-ALPHA-SYNUCLEIN THERAPEUTIC VACCINES Pending CA3248093A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22156006.3 2022-02-09
EP22156006 2022-02-09
EP22156007.1 2022-02-09
EP22156007 2022-02-09
PCT/EP2023/053259 WO2023152260A1 (en) 2022-02-09 2023-02-09 Anti-alpha-synuclein therapeutic vaccines

Publications (1)

Publication Number Publication Date
CA3248093A1 true CA3248093A1 (en) 2023-08-17

Family

ID=85175955

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3248093A Pending CA3248093A1 (en) 2022-02-09 2023-02-09 ANTI-ALPHA-SYNUCLEIN THERAPEUTIC VACCINES

Country Status (11)

Country Link
US (1) US20250152684A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475878A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506472A (cg-RX-API-DMAC7.html)
KR (1) KR20240147981A (cg-RX-API-DMAC7.html)
AU (1) AU2023219059A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248093A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002370A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240371A (cg-RX-API-DMAC7.html)
IL (1) IL314865A (cg-RX-API-DMAC7.html)
MX (1) MX2024009485A (cg-RX-API-DMAC7.html)
WO (1) WO2023152260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250135293A (ko) * 2023-01-26 2025-09-12 에이씨 이뮨 에스에이 리포좀 구조체
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
WO2013173827A2 (en) * 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta
JP7898188B2 (ja) * 2020-08-04 2026-07-31 エイシー イミューン ソシエテ アノニム 免疫原性化合物

Also Published As

Publication number Publication date
US20250152684A1 (en) 2025-05-15
IL314865A (en) 2024-10-01
EP4475878A1 (en) 2024-12-18
CR20240371A (es) 2024-10-16
WO2023152260A1 (en) 2023-08-17
KR20240147981A (ko) 2024-10-10
JP2025506472A (ja) 2025-03-11
AU2023219059A1 (en) 2024-07-25
MX2024009485A (es) 2024-08-14
CL2024002370A1 (es) 2024-12-27

Similar Documents

Publication Publication Date Title
US20250326806A1 (en) Compositions of Phosphorylated Tau Peptides and Uses Thereof
US12324855B2 (en) Method of safe administration of phosphorylated Tau peptide vaccine
US20230257433A1 (en) Heterologous Administration of Tau Vaccines
KR102869640B1 (ko) 항-aveta 치료적 백신
US20250152684A1 (en) Anti-Alpha-Synuclein Therapeutic Vaccines
US20230287050A1 (en) Immunogenic Compounds
EA051687B1 (ru) Терапевтические вакцины против альфа-синуклеина
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
HK40087814A (en) Immunogenic compounds
EA048154B1 (ru) Иммуногенные соединения
HK40105209A (en) Compositions of phosphorylated tau peptides and uses thereof
CN120583938A (zh) 脂质体构建体
CN112165956A (zh) 抗Aβ治疗性疫苗
HK40043189A (en) Anti-abeta therapeutic vaccines

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240709

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241122

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241122

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241122

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241126

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250107

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260114